|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
PHAGOCYTES
From the Department of Genetics and Department of
Clinical Oncology, Institute of Medical Science, University of Tokyo,
and Tokyo Research Laboratories, Kyowa Hakko Kogyo Co, Ltd, Japan.
Flt-1, also known as vascular endothelial growth factor receptor 1 (VEGFR-1), is a high-affinity tyrosine kinase receptor for VEGF and is
expressed almost exclusively on vascular endothelial cells. As an
exception, Flt-1 transcript was recently found to be expressed in human
peripheral blood monocytes. However, the protein of the Flt-1 receptor
on the cell surface of monocytes is yet to be identified, and whether
the Flt-1 protein is expressed during the differentiation of
monocyte-macrophage lineage cells has not been examined. Using
monoclonal antibodies against 2 different antigenic epitopes on the
Flt-1 extracellular domain, this study found that the major population
of the monocyte-marker CD97+ cells in human peripheral
blood express Flt-1 as a cell surface molecule. VEGFR-2 (KDR/Flk-1) was
not expressed at detectable levels in these cells. An Flt-1
neutralizing monoclonal antibody significantly suppressed VEGF-induced
migration of the monocytes, suggesting an important role for Flt-1 in
the biologic function of monocytes. Furthermore, CD34+
cells in human cord blood, originally negative for the Flt-1 expression, differentiated into Flt-1+ cells in association
with the appearance of monocyte-macrophage markers after a 2-week
culture in the presence of hematopoietic cytokines. In addition, the
Flt-1+CD11b+ cell fraction from
CD34+ cells was found to efficiently differentiate into
multinuclear osteoclasts in the presence of macrophage
colony-stimulating factor and osteoclast differentiation factor. These
results strongly suggest that Flt-1 is a novel cell surface
marker as well as a biologically functional molecule for
monocyte-macrophage lineages in humans.
(Blood. 2001;97:785-791) Vascular endothelial growth factor (VEGF) and its
receptors Flt-1 (VEGFR-1) and KDR/Flk-1 (VEGFR-2) are well established
as the essential regulatory system for blood vessel formation in embryogenesis.1-4 Other VEGF family members such as VEGF-C
and VEGF-D and their specific receptor Flt-4 (VEGFR-3) are also
important for angiogenesis as well as lymphoangiogenesis in the
embryo.5 The specificity of VEGF and its receptor system
for vascular endothelial cells appears to be based on at least 2 factors, the endothelial cell-specific expression of Flt-1 and
KDR/Flk-16,7 and a unique signaling pathway from the
receptors. We have recently shown that VEGF-dependent DNA synthesis in
primary endothelial cells is mainly mediated via the phospholipase
C Most of the signals for VEGF-induced cell proliferation and vascular
permeability are considered to be mediated by KDR/Flk-1, which has
strong tyrosine kinase activity.10-12 On the other hand, the Flt-1 bears an affinity for VEGF that is about 10-fold higher than
KDR, but contains much weaker tyrosine kinase activity, suggesting a
regulatory function in the VEGF signaling in endothelial
cells.13-16
Recently, in addition to vascular endothelial cells, human peripheral
blood monocytes were reported to express flt-1 gene messenger RNA (mRNA).17,18 A population of these cells
showed a VEGF-mediated migration even in the presence of
KDR-neutralizing polyclonal antibody, suggesting that this cell
migration signal is mediated by Flt-1.18 We have recently
demonstrated that Flt-1 tyrosine kinase domain-deficient mice lost the
capacity for VEGF-dependent cell migration of peritoneal macrophages,
indicating that the Flt-1 tyrosine kinase activity is important for the
VEGF-induced cell migration of macrophages in mice.16
Although these results strongly suggest an intimate relationship
between Flt-1 and the monocyte-macrophage lineages, it is still not
clear which population of monocyte-macrophages expresses the Flt-1
molecule and carries the Flt-1-dependent signaling pathway, because
monoclonal antibodies (mAbs) against the extracellular domain of Flt-1
have not been established yet.
Monocyte-macrophages are known to differentiate into a variety of cell
types such as osteoclasts in bone, Kupffer cells in liver, dendritic
cells in the immune system, and mature macrophages in a number of
tissues. Furthermore, they are involved in a variety of major diseases
such as inflammation, metabolic diseases, and cancer. Therefore, it
appears important to clarify in which population of
monocyte-macrophages Flt-1 is expressed on the cell surface and is
biologically functional. In addition, because Flt-1 is a transmembrane
receptor-type molecule, it seems worth examining whether it is useful
as a cell surface marker for the differentiation of monocyte-macrophage
lineages in FACS analysis.
To address these issues, we have established a series of mAbs against
Flt-1 in humans. Here we report that Flt-1 but not KDR/Flk-1 is a novel
cell surface marker for monocyte-macrophage lineages in adults and is
gradually up-regulated during the differentiation and maturation of
macrophages originating from the CD34+ hematopoietic
progenitor cells in cord blood.
Cells
Preparation of soluble VEGF receptors
Anti-VEGF receptors mAbs The production of antihuman Flt-1 mAbs including KM1730 (mouse IgG1) and KM1732 (mouse IgG1) and antihuman KDR mAb including KM1992 (mouse IgG1) and KM1995 (mouse IgG2b) was carried out as follows. B3C3F1 mice (Charles River Japan, Kanagawa, Japan) at 6 to 8 weeks old were immunized by intraperitoneal injection of Flt-1 7N or KDR 5 1N-Fc. Spleen cells were fused with mouse myeloma cells and
hybridoma cells producing the mAbs reactive with Flt-1 3N or KDR 7N-Fc
were selected. Antihuman Flt-1 mAbs KM1730 and KM1732 react with the
second Ig-like domain of Flt-1 and antihuman KDR mAbs KM1992 and KM1995
react with the fourth Ig-like domain of KDR. Mouse IgG1 mAb KM1135 or
KM231 was used as a control mAb.
VEGF binding assay for soluble VEGF receptors Fifty µL/well of 1.6 µg/mL Flt-1 7N or 4 µg/mL KDR 7N-Fc in phosphate-buffered saline (PBS, 137 mM NaCl, 2.7 mM KCl, 9.7 mM sodium phosphate buffer, pH 7.4) was applied to the surface of methanol-treated 96-well immobilon-P filtration plates (Millipore, Bedford, MA) overnight at 4°C, and nonspecific binding sites were blocked with 1% bovine serum albumin (BSA) in PBS. After 3 washes with PBS, 50 µL purified mAbs as competitor and 50 µL of 3 ng/mL [125]I-VEGF (Amersham-Pharmacia Biotech, Buckinghamshire, England) were added to each well and allowed to react for 1.5 hours at room temperature. After 3 washes with 0.05% Tween 20 in PBS, 30 µL microscinti-o (Packard, Meriden, CT) was added to each well and the radioactivity was measured in Topcount (Packard).Flow cytometric analysis Biotinylation of mAb was performed as described by Shitara and colleagues.22 For indirect immunofluorescence, the NIH 3T3-Flt-1 cells, NIH 3T3-KDR cells, NIH 3T3-Neo cells, or HUVECs (1 × 106) were incubated with 10 µg/mL mAbs or biotinylated mAbs for 30 minutes at 4°C. After the reaction with 30-fold diluted fluorescein isothiocyanate (FITC)-conjugated rabbit F(ab)'2 antimouse IgG (H+L) (Wako, Osaka, Japan) or 5 µg/mL streptavidin-phycoerythrin (Gibco, Gaithersburg, MD), the reactivity was analyzed in an EPICS Elite flow cytometer (Beckman-Coulter, Fullerton, CA).Reaction of anti-Flt-1 and other antibodies with human peripheral monocytes The mononuclear cells were isolated from human adult peripheral blood by the Ficoll/Paque density gradient method. The mononuclear cells were washed once with PBS, then suspended in 0.1% BSA-containing PBS. An aliquot of the mononuclear cells (3 × 106) was incubated with FITC-labeled anti-CD97 antibody (Pharmingen, San Diego, CA), phycoerythrin (PE)-labeled anti-CD11c antibody (Beckman-Coulter), and biotin-labeled anti-CD11b (Beckman-Coulter), respectively, at room temperature for 15 minutes. The samples were washed by centrifugation, reacted with streptavidin-APC (Becton Dickinson, Franklin Lakes, NJ), then once washed, and analyzed with an EPICS Elite flow cytometer (Beckman-Coulter).For double labeling with anti-Flt-1 mAb KM1730 and anti-CD34 antibody, 3 × 106 mononuclear cells in 0.3 mL 0.1% BSA-PBS were incubated with anti-Flt-1 mAb KM1730 at room temperature for 15 minutes. After a wash, the cells were resuspended in 300 µL 0.1% BSA-PBS and reacted with PE-labeled antimouse-IgG goat antibody (Becton Dickinson). The cells were washed, then reacted with PC5-labeled anti-CD34 (Beckman-Coulter) at room temperature for 15 minutes. The cells were washed again and analyzed by flow cytometry. For the double labeling of monocytes with anti-Flt-1 and anti-CD97 mAbs,23 the mononuclear cells were first reacted with anti-Flt-1 mAb KM1730, then with PE-labeled antimouse-IgG goat antibody as described above. Next, the cells were reacted with FITC-labeled anti-CD97 antibody (Pharmingen). After washing the samples were analyzed by flow cytometry. VEGF-dependent monocyte migration About 2 × 107 mononuclear cells obtained from healthy adult human peripheral blood were suspended in 10 mL 10% fetal calf serum (FCS; JRH Biosciences, Lenexa, KS) and kanamycin (40 µg/mL)-containing RPMI 1640 medium. The cells were plated on a culture dish that was preincubated with 10% FCS-RPMI 1640 overnight, and incubated at 37°C for 2 hours to attach the monocytes. Nonattached cells were removed from the plate and the attached monocytes were washed twice with PBS. The monocytes were recovered by incubating these plates with 5 mL 0.2% EDTA-containing 5% FCS-PBS for 20 minutes. The monocytes were washed 3 times with 10% FCS-RPMI 1640, and suspended at 1 × 106/mL in 0.5% FCS-RPMI 1640.For the cell migration assay, a Neuroprobe 48-well microchemotaxis
chamber (Neuroprobe, Bethesda, MD) was used. In the lower chamber, 25 µL 0.5% FCS-RPMI 1640 medium was added with or without purified recombinant VEGF. In some wells of the lower chamber, a
neutralizing mAb against Flt-1 (KM1732) was added at 1 µg/mL. As a
positive control, fMLP (N-formyl-methyonyl-leucyl-phenylalanine; Sigma,
St Louis, MO) was added at a concentration of 5 nM. A filter (5-µm-pore-size PVP( In addition, macrophagelike cells were obtained from cord blood cells after a 12- to 14-day culture (see below) and used for cell migration assay as indicated for peripheral blood monocytes. In vitro culture of cord blood CD34+ cells for the proliferation and differentiation of macrophagelike cells A mononuclear cell fraction containing monocytes and lymphocytes was isolated from human cord blood of placenta by Ficoll/Paque density gradient centrifugation. These cells were washed once with PBS, then suspended in 0.1% BSA-PBS. Mononuclear cells (3 × 106) in 0.3 mL 0.1% BSA-PBS were added with anti-Flt-1 mAb KM1730 and incubated at room temperature for 15 minutes. After being washed, the cells were reacted with PE-labeled antimouse-IgG goat antibody at room temperature for 15 minutes.The cells were washed and reacted with PC5-labeled anti-CD34 antibody (Beckman-Coulter) and FITC-labeled anti-CD38 antibody (Beckman-Coulter) for 15 minutes. After washing, the cells were analyzed by flow cytometry. The CD34+CD38+ cell fraction was
recovered by cell sorting, and the cells were incubated at 37°C for
12 to 14 days under 5% CO2 in 30% FCS containing
Differentiation of macrophagelike cells to osteoclasts in vitro Macrophagelike cells obtained from CD34+ cells after a 2-week incubation were washed and recultured with M-CSF and ODF (osteoclast differentiation factor)/OPGL (osteoproteregin ligand)/sRANKL (soluble RANK ligand)25,26 in fibronectin-coated dishes for 10 days. After the culture, cells were examined for phagocytic activity and for vitronectin receptor expression. For phagocytosis assay, cultured osteoclasts and macrophages were incubated with diluted (1 × 107/mL) yellow-green fluorescent beads, whose diameters were around 2 µm (Polysciences, Warrington, PA) for 2 hours at 37°C in a humidified atmosphere flushed with 5% CO2 in air. Then, adherent cells were washed 3 times with PBS and fixed with 5% formaldehyde for 15 minutes at room temperature. In addition, osteoclasts were specifically stained with antivitronectin receptor mAb (a mixture of anti-CD51 and anti-CD61 mAbs or clone 23C6 mAb) and detected with alkaline phosphatase antialkaline phosphatase (APAAP).27
The mAbs against the extracellular domain of Flt-1 recognize the cell surface-expressed Flt-1 but not KDR/Flk-1 To obtain mAbs against Flt-1, several constructs of the extracellular domain of human Flt-1 were expressed in the Baculovirus-insect cell system, and the purified peptides were used as antigens to immunize mice. In parallel, mAbs against human KDR were prepared in a similar procedure (see "Materials and methods").Figures 1 and
2 indicate the specificity of the
anti-Flt-1 mAbs. The KM1730 and KM1732 anti-Flt-1 mAbs recognized the
Flt-1 expressed on the surface of NIH 3T3 cells, but not the KDR
expressed on NIH 3T3 cells (Figure 1A). In addition, KM1732, which
recognizes the second Ig domain of Flt-1, blocked the binding of VEGF
to Flt-1 but not to KDR, indicating that KM1732 is a neutralizing mAb
(Figure 2A). The second Ig region of Flt-1 and its surrounding structures were previously shown to be the direct binding site for
VEGF.20,28,29 These anti-Flt-1 mAbs also recognized Flt-1 endogenously expressed on HUVECs (Figure 2B). On the other hand, anti-KDR mAbs, KM1992 and KM1995, recognized only the KDR molecule expressed on HUVECs and NIH 3T3 cells (Figures 1B,2B).
The major population of human peripheral blood monocytes expresses Flt-1 as a cell surface molecule To examine whether Flt-1 is present on the cell surface of adult human monocytes, we carried out a cell fractionation study of normal monocytes by cell sorting of human peripheral blood mononuclear cells. With the cell size and the cell complexity as markers, we obtained a monocyte fraction (Figure 3A, M-fraction). We have previously shown that this M-fraction basically contains peripheral blood monocytes. In this fraction, cells were positive for CD97 (about 90%) as well as for CD11b and CD11c (58% and 75%, respectively), confirming that they are of monocyte-macrophage lineage30 (Figure 3B,C). CD97 in humans is known to be structurally closely related to a macrophage marker F4/80 in mice.
When these cells were sorted with anti-Flt-1 mAb KM1730 labeled
with PE, at least 2 cellular populations were obtained. About 83% of
the M-fraction clearly expressed human Flt-1 on the cell surface,
whereas about 17% of these cells were only very weakly Flt-1+ or Flt-1
Therefore, we conclude that human peripheral blood monocytes can be separated into 2 populations in terms of the expression level of Flt-1, and that the major population of monocytes are clearly Flt-1+. The Flt-1 receptor is involved in monocyte migration Next we examined the biologic significance of the Flt-1 expressed in peripheral cells of monocyte-macrophage lineage. Monocytes were selected from peripheral mononuclear cells by attachment to culture dishes and examined for VEGF-dependent cell migration using a Neuroprobe microchemotaxis chamber. As shown in Figure 4A, VEGF stimulated cell migration in a dose-dependent manner, but at doses higher than 40 ng/mL, it was rather suppressive. Suppression of cell migration at higher doses of VEGF was also observed by other investigators.17,18 A neutralizing mAb KM1732 against Flt-1, which binds the second Ig region of Flt-1 and blocks VEGF binding to Flt-1, efficiently suppressed this VEGF-induced monocyte migration.
To further confirm VEGF-dependent monocyte-macrophage cell migration and its suppression by anti-Flt-1-neutralizing mAb, CD34+ cord blood cells were differentiated into macrophage lineage (see below and "Materials and methods") and the macrophagelike cells were used for cell migration assay. We obtained essentially the same results as monocytes in peripheral blood (Figure 4B). On the other hand, KM1732 mAb did not alter the cell migration in negative control (minus VEGF) nor that in positive control with fMLP. These results suggest that the Flt-1 expressed on the cell surface is important to the functions of monocyte-macrophages such as ligand-dependent cell migration. Generation of macrophagelike cells from CD34+ hematopoietic progenitor cells is associated with the expression of Flt-1 on the cell surface To see whether we could induce the expression of Flt-1 on the cell surface in vitro under conditions of commitment and differentiation into cells of macrophage lineage, we took advantage of cord blood of placenta, which contains a relatively high percentage of pluripotent progenitor cells compared with peripheral blood mononuclear cells in adult stages. The CD34+ cells, shown to be mainly hematopoietic progenitor cells in the embryo,30 were isolated by a sorting procedure. About 90% of these cells were CD97 , and so not of the monocyte-macrophage lineage
(Figure 5A,B). More than 95% of these
CD34+ cells were also Flt-1, as determined
with anti-Flt-1 mAb KM1730 (Figure 5C).
The fraction of CD34+CD38+ cells was isolated
by cell sorting and cultured for 12 to 14 days in the presence of a
cytokine mixture (IL-3, IL-6, Flt-3 ligand, GM-CSF, and M-CSF). The
CD34+CD38+ cell fraction covers about 95% of
total CD34+ cell population (Figure 5D) and is known to
efficiently respond to cytokines for colony formation. After this
long-term culture, a large population of macrophagelike cells was found
to be generated based on the cell size and complexity (Figure 5E). This
macrophagelike cell fraction was isolated and further examined for the
expression of monocyte-macrophage marker CD97 and Flt-1. As indicated
in Figure 5F, about 98% of these cells expressed CD97, indicating proliferation and differentiation of the progenitor cells into macrophage-lineage cells. Interestingly, these cells separated into at
least 2 major subpopulations, Flt-1 negative to weakly positive and
Flt-1 strongly positive (Figure 5G, 6A).
In an average of 6 experiments, Flt-1 weakly positive cells were
44.7% ± 13.2% and Flt-1 strongly positive cells were
20.1% ± 4.7% (Table 2). Therefore,
these results clearly indicate that under culture conditions for
differentiation into macrophage-lineage cells, Flt-1 is expressed on
the cell surface. The different levels of Flt-1 in macrophagelike cells
suggest that the commitment and differentiation into a mature macrophage is a stepwise process, and that Flt-1 is a useful marker for
distinguishing these subpopulations.
Differentiation of Flt-1+CD11b+ cells into multinuclear osteoclasts in vitro Recently, VEGF has been shown to be closely involved in bone remodeling in vivo.31,32 To examine the characteristics of the Flt-1+ cells obtained from the CD34+ population in vitro, particularly in terms of the potentiality to differentiate into osteoclasts, we collected the Flt-1+CD11b+ cells and Flt-1++CD11b++ cells, separately (Figure 6A), and further cultured them with M-CSF and ODF for 10 days.Vitronectin receptors (VNR) are known to be a specific cell marker for osteoclasts. VNR+ osteoclasts were obtained both from Flt-1+CD11b+ cells and Flt-1++CD11b++ cells (Figure 6B). However, the number of multinuclear osteoclasts in the Flt-1+CD11b+ cell fraction was about 4-fold that in the Flt-1++CD11b++ fraction (Figure 6B,C). Further, the numbers of macrophages surrounding the osteoclasts markedly increased in Flt-1+CD11b+ cells during the culture, whereas the macrophagelike cells in the Flt-1++CD11b++ fraction did not proliferate even in the presence of these cytokines (Figure 6). These results suggest that although the Flt-1++CD11b++ cells still contain osteoclast precursor cells as well as macrophages, they are highly differentiated and have lost the potential to proliferate. Physiologic osteoclasts are essentially multinuclear giant cells morphologically very similar to those in Figure 6B; thus, we conclude that the Flt-1+CD11b+ cell fraction bears the normal osteoclast precursor cells and retains cell proliferative activity.
Flt-1 tyrosine kinase was originally isolated as a new type of receptor tyrosine kinase specifically expressed on vascular endothelial cells as well as in placental tissue.33-36 In this study, we have shown that, in addition to vascular endothelial cells and placental trophoblasts, Flt-1 is a useful cell surface marker for monocyte-macrophages in humans. Recently, VEGF has been shown to participate the differentiation and function of chondroclasts and osteoclasts in vivo.31,32 Therefore, our results seem consistent with those of other reports. We previously reported that the cell type-specific flt-1
gene expression is regulated by cooperation between the Ets family and
CRE/ATF family transcription factors.37 Furthermore, we demonstrated that at least a part of the cellular signaling from Flt-1
is mediated via the PLC
We thank Drs Tatsuo Suda and Naoyuki Takahashi (Showa University Medical School, Tokyo) for supplying ODF.
Submitted April 12, 2000; accepted October 9, 2000.
Supported by Grants-in-Aid for Special Project Research on Cancer- Bioscience 04253204 from the Ministry of Education in Japan and for the program "Research for the Future" of the Japan Society for Promotion of Science.
A.S. and S.I. contributed equally to this work.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Masabumi Shibuya, Department of Genetics, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokane-dai, Minato-ku, Tokyo 108-8639, Japan; e-mail: shibuya{at}ims.u-tokyo.ac.jp.
1. Risau W. Mechanism of angiogenesis. Nature. 1997;386:671-674[CrossRef][Medline] [Order article via Infotrieve].
2.
Ferrara N, Davis-Smyth T.
The biology of vascular endothelial growth factor.
Endocr Rev.
1997;18:4-25 3. Shibuya M. Role of VEGF-Flt receptor system in normal and tumor angiogenesis. Adv Cancer Res. 1995;67:281-316[Medline] [Order article via Infotrieve]. 4. Shibuya M, Ito N, Claesson-Welsh L. Structure and function of VEGF receptor-1 and -2. Curr Top Microbiol Immunol. 1999;237:59-83[Medline] [Order article via Infotrieve].
5.
Mustonen T, Alitalo K.
Endothelial receptor tyrosine kinases involved in angiogenesis.
J Cell Biol.
1995;129:895-898 6. Jakeman L, Winer J, Bennett GL, Alter CA, Ferrara N. Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J Clin Invest. 1992;89:244-253. 7. Yamane A, Seetharam L, Yamaguchi S, et al. A new communication system between hepatocytes and sinusoidal endothelial cells in liver through vascular endothelial growth factor and Flt tyrosine kinase receptor family (Flt-1 and KDR/Flk-1). Oncogene. 1994;9:2683-2690[Medline] [Order article via Infotrieve].
8.
Takahashi T, Shibuya M.
The 230kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC 9. Takahashi T, Ueno H, Shibuya M. VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene. 1999;18:2221-2230[CrossRef][Medline] [Order article via Infotrieve]. 10. Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature. 1995;376:62-66[CrossRef][Medline] [Order article via Infotrieve].
11.
Ogawa S, Oku A, Sawano A, Yamaguchi S, Yazaki Y, Shibuya M.
A novel type of vascular endothelial growth factor: VEGF-E (NZ-7 VEGF) preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain.
J Biol Chem.
1998;273:31273-31282 12. Carmeliet P, Lampugnani MG, Moons L, et al. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell. 1999;98:147-157[CrossRef][Medline] [Order article via Infotrieve].
13.
Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH.
Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor.
J Biol Chem.
1994;269:26988-26995 14. Sawano A, Takahashi T, Yamaguchi S, Aonuma T, Shibuya M. Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor (PlGF), which is related to vascular endothelial growth factor (VEGF). Cell Growth Differ. 1996;7:213-221[Abstract]. 15. Fong GH, Rossant J, Gertsentein M, Breitman ML. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature. 1995;376:66-70[CrossRef][Medline] [Order article via Infotrieve].
16.
Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M.
Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice.
Proc Natl Acad Sci U S A.
1998;95:9349-9354
17.
Clauss M, Weicht H, Breier G, et al.
The vascular endothelial growth factor receptor Flt-1 mediates biological activities.
J Biol Chem.
1996;271:17629-17634
18.
Barleon B, Sozzani S, Zhou D, Weich HA, Martovani A, Marme D.
Migration of human monocytes in response to vascular endothelilal growth factor (VEGF) is mediated via the VEGF receptor flt-1.
Blood.
1996;87:3336-3343 19. Seetharam L, Gotoh N, Maru Y, Neufeld G, Yamaguchi S, Shibuya M. A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. Oncogene. 1995;10:135-147[Medline] [Order article via Infotrieve]. 20. Tanaka K, Yamaguchi S, Sawano A, Shibuya M. Characterization of the extracellular domain in the vascular endothelial growth factor receptor-1 (Flt-1 tyrosine kinase). Jpn J Cancer Res. 1997;88:867-876[CrossRef][Medline] [Order article via Infotrieve].
21.
Shinkai A, Ito M, Anazawa H, Yamaguchi S, Shitara K, Shibuya M.
Mapping of the sites involved in ligand-association and dissociation at the extracellular domain of vascular endothelial growth factor receptor KDR.
J Biol Chem.
1998;273:31283-31288
22.
Shitara K, Hanai N, Yoshida H.
Distribution of lung adenocarcinoma-associated antigens in human tissues and sera defined by monoclonal antibodies KM-52 and KM-93.
Cancer Res.
1987;47:1267-1272 23. Kishimoto T, Kikutani H, von dem Borne A, et al. Leukocyte Typing VI. New York: Garland Publishing; 1997.
24.
Xu MJ, Tsuji K, Ueda T, et al.
Stimulation of mouse and human primitive hematopoiesis by murine embryonic aorta-gonad-mesonephros-derived stromal cell lines.
Blood.
1998;92:2032-2040 25. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:165-176[CrossRef][Medline] [Order article via Infotrieve].
26.
Yasuda H, Shima N, Nakagawa N, et al.
Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.
Proc Natl Acad Sci U S A.
1998;95:3597-3602 27. Sui X, Tsuji K, Tajima S, et al. Erythropoietin-independent erythrocyte production: signals through gp130 and c-kit dramatically promote erythropoiesis from human CD34+ cells. J Exp Med. 1996;1:837-845. 28. Davis-Smyth T, Chen H, Park J, Presta LG, Ferrara N. The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade. EMBO J. 1996;15:4919-4927[Medline] [Order article via Infotrieve].
29.
Barleon B, Totzke F, Herzog C, et al.
Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the vascular endothelial growth factor receptor FLT-1.
J Biol Chem.
1997;272:10382-10388
30.
Tajima S, Tsuji K, Ebihara Y, et al.
Analysis of interleukin 6 receptor and gp130 expressions and proliferative capability of human cd34+ cells.
J Exp Med.
1996;184:1357-1364 31. Gerber HP, Vu TH, Ryan AM, Kowalski J, Werb Z, Ferrara N. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med. 1999;5:623-628[CrossRef][Medline] [Order article via Infotrieve].
32.
Niida S, Kaku M, Amano H, et al.
Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption.
J Exp Med.
1999;190:293-298 33. Shibuya M, Yamaguchi S, Yamane A, et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene. 1990;5:519-524[Medline] [Order article via Infotrieve].
34.
De Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams T.
The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor.
Science.
1992;255:989-991
35.
Peters KG, De Vries C, Williams LT.
Vascular endothelial growth factor receptor expression during embryogenesis and tissue repair suggests a role in endothelial differentiation and blood vessel growth.
Proc Natl Acad Sci U S A.
1993;90:8915-8919
36.
Kaipainen A, Korhonen J, Pajusola K, et al.
The related FLT4, FLT1, and KDR receptor tyrosine kinases show distinct expression patterns in human fetal endothelial cells.
J Exp Med.
1993;178:2077-2088
37.
Wakiya K, Begue A, Stehelin D, Shibuya M.
A cyclic AMP response element and an ETS motif are involved in the transcriptional regulation of flt-1 tyrosine kinase (VEGF receptor 1) gene.
J Biol Chem.
1996;271:30823-30828
38.
Sawano A, Takahashi T, Yamaguchi S, Shibuya M.
The phosphorylated 1169-tyrosine containing region of Flt-1 kinase (VEGFR-1) is a major binding site for PLC
© 2001 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  X. Li, C. Hanson, J. L. Cmarik, and S. Ruscetti Neurodegeneration Induced by PVC-211 Murine Leukemia Virus Is Associated with Increased Levels of Vascular Endothelial Growth Factor and Macrophage Inflammatory Protein 1{alpha} and Is Inhibited by Blocking Activation of Microglia J. Virol., May 15, 2009; 83(10): 4912 - 4922. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Way, H. Dinh, M. R. Keene, K. E. White, F. I. L. Clanchy, P. Lusby, J. Roiniotis, A. D. Cook, A. I. Cassady, D. J. Curtis, et al. The generation and properties of human macrophage populations from hemopoietic stem cells J. Leukoc. Biol., May 1, 2009; 85(5): 766 - 778. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Mu, D. A. Long, X. Ouyang, A. Agarwal, P. E. Cruz, C. A. Roncal, T. Nakagawa, X. Yu, W. W. Hauswirth, and R. J. Johnson Angiostatin overexpression is associated with an improvement in chronic kidney injury by an anti-inflammatory mechanism Am J Physiol Renal Physiol, January 1, 2009; 296(1): F145 - F152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ponticelli, D. Marasco, V. Tarallo, R. J. C. Albuquerque, S. Mitola, A. Takeda, J.-M. Stassen, M. Presta, J. Ambati, M. Ruvo, et al. Modulation of Angiogenesis by a Tetrameric Tripeptide That Antagonizes Vascular Endothelial Growth Factor Receptor 1 J. Biol. Chem., December 5, 2008; 283(49): 34250 - 34259. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kerber, Y. Reiss, A. Wickersheim, M. Jugold, F. Kiessling, M. Heil, V. Tchaikovski, J. Waltenberger, M. Shibuya, K. H. Plate, et al. Flt-1 Signaling in Macrophages Promotes Glioma Growth In vivo Cancer Res., September 15, 2008; 68(18): 7342 - 7351. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-i. Nishi, T. Minamino, H. Miyauchi, A. Nojima, K. Tateno, S. Okada, M. Orimo, J. Moriya, G.-H. Fong, K. Sunagawa, et al. Vascular Endothelial Growth Factor Receptor-1 Regulates Postnatal Angiogenesis Through Inhibition of the Excessive Activation of Akt Circ. Res., August 1, 2008; 103(3): 261 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Halin, H. Fahrngruber, J. G. Meingassner, G. Bold, A. Littlewood-Evans, A. Stuetz, and M. Detmar Inhibition of Chronic and Acute Skin Inflammation by Treatment with a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Am. J. Pathol., July 1, 2008; 173(1): 265 - 277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. P. Dineen, K. D. Lynn, S. E. Holloway, A. F. Miller, J. P. Sullivan, D. S. Shames, A. W. Beck, C. C. Barnett, J. B. Fleming, and R. A. Brekken Vascular Endothelial Growth Factor Receptor 2 Mediates Macrophage Infiltration into Orthotopic Pancreatic Tumors in Mice Cancer Res., June 1, 2008; 68(11): 4340 - 4346. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Izumi-Nagai, N. Nagai, K. Ohgami, S. Satofuka, Y. Ozawa, K. Tsubota, S. Ohno, Y. Oike, and S. Ishida Inhibition of Choroidal Neovascularization with an Anti-Inflammatory Carotenoid Astaxanthin Invest. Ophthalmol. Vis. Sci., April 1, 2008; 49(4): 1679 - 1685. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Murakami, Y. Zheng, M. Hirashima, T. Suda, Y. Morita, J. Ooehara, H. Ema, G.-H. Fong, and M. Shibuya VEGFR1 Tyrosine Kinase Signaling Promotes Lymphangiogenesis as Well as Angiogenesis Indirectly via Macrophage Recruitment Arterioscler. Thromb. Vasc. Biol., April 1, 2008; 28(4): 658 - 664. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Soro, A. Orecchia, L. Morbidelli, P. M. Lacal, V. Morea, K. Ballmer-Hofer, F. Ruffini, M. Ziche, S. D'Atri, G. Zambruno, et al. A proangiogenic peptide derived from vascular endothelial growth factor receptor-1 acts through {alpha}5{beta}1 integrin Blood, April 1, 2008; 111(7): 3479 - 3488. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Xing, F. G. Hage, Y.-F. Chen, M. A. McCrory, W. Feng, G. A. Skibinski, E. Majid-Hassan, S. Oparil, and A. J. Szalai Exaggerated Neointima Formation in Human C-Reactive Protein Transgenic Mice Is IgG Fc Receptor Type I (Fc{gamma}RI)-Dependent Am. J. Pathol., January 1, 2008; 172(1): 22 - 30. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Itaya, E. Sakurai, M. Nozaki, K. Yamada, S. Yamasaki, K. Asai, and Y. Ogura Upregulation of VEGF in Murine Retina via Monocyte Recruitment after Retinal Scatter Laser Photocoagulation Invest. Ophthalmol. Vis. Sci., December 1, 2007; 48(12): 5677 - 5683. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Lima e Silva, J. Shen, S. F. Hackett, S. Kachi, H. Akiyama, K. Kiuchi, K. Yokoi, M. C. Hatara, T. Lauer, S. Aslam, et al. The SDF-1/CXCR4 ligand/receptor pair is an important contributor to several types of ocular neovascularization FASEB J, October 1, 2007; 21(12): 3219 - 3230. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-S. Choi, H.-Y. Kim, J.-H. Cha, J.-Y. Choi, S. I. Park, C. H. Jeong, S.-S. Jeun, and M.-Y. Lee Upregulation of Vascular Endothelial Growth Factor Receptors Flt-1 and Flk-1 Following Acute Spinal Cord Contusion in Rats J. Histochem. Cytochem., August 1, 2007; 55(8): 821 - 830. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Huang, X. Chen, M. M. Dikov, S. V. Novitskiy, C. A. Mosse, L. Yang, and D. P. Carbone Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF Blood, July 15, 2007; 110(2): 624 - 631. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Krenn, W. Klepetko, S. Taghavi, P. Paulus, and S. Aharinejad Vascular endothelial growth factor increases pulmonary vascular permeability in cystic fibrosis patients undergoing lung transplantation Eur. J. Cardiothorac. Surg., July 1, 2007; 32(1): 35 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Nagano, T. Yamashita, H. Hamada, K. Ohneda, K.-i. Kimura, T. Nakagawa, M. Shibuya, H. Yoshikawa, and O. Ohneda Identification of functional endothelial progenitor cells suitable for the treatment of ischemic tissue using human umbilical cord blood Blood, July 1, 2007; 110(1): 151 - 160. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Norden-Zfoni, J. Desai, J. Manola, P. Beaudry, J. Force, R. Maki, J. Folkman, C. Bello, C. Baum, S. E. DePrimo, et al. Blood-Based Biomarkers of SU11248 Activity and Clinical Outcome in Patients with Metastatic Imatinib-Resistant Gastrointestinal Stromal Tumor Clin. Cancer Res., May 1, 2007; 13(9): 2643 - 2650. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Raisky, A. I. Nykanen, R. Krebs, M. Hollmen, M. A.I. Keranen, J. M. Tikkanen, R. Sihvola, L. Alhonen, P. Salven, Y. Wu, et al. VEGFR-1 and -2 Regulate Inflammation, Myocardial Angiogenesis, and Arteriosclerosis in Chronically Rejecting Cardiac Allografts Arterioscler. Thromb. Vasc. Biol., April 1, 2007; 27(4): 819 - 825. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Shinoda, K. Umeda, T. Heike, M. Arai, A. Niwa, F. Ma, H. Suemori, H. Y. Luo, D. H. K. Chui, R. Torii, et al. {alpha}4-Integrin+ endothelium derived from primate embryonic stem cells generates primitive and definitive hematopoietic cells Blood, March 15, 2007; 109(6): 2406 - 2415. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Srikiatkhachorn, C. Ajariyakhajorn, T. P. Endy, S. Kalayanarooj, D. H. Libraty, S. Green, F. A. Ennis, and A. L. Rothman Virus-Induced Decline in Soluble Vascular Endothelial Growth Receptor 2 Is Associated with Plasma Leakage in Dengue Hemorrhagic Fever J. Virol., February 15, 2007; 81(4): 1592 - 1600. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Satofuka, A. Ichihara, N. Nagai, T. Koto, H. Shinoda, K. Noda, Y. Ozawa, M. Inoue, K. Tsubota, H. Itoh, et al. Role of Nonproteolytically Activated Prorenin in Pathologic, but Not Physiologic, Retinal Neovascularization Invest. Ophthalmol. Vis. Sci., January 1, 2007; 48(1): 422 - 429. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. N. Kaplan, S. Rafii, and D. Lyden Preparing the "Soil": The Premetastatic Niche Cancer Res., December 1, 2006; 66(23): 11089 - 11093. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. M. Dirkx, M. G. A. oude Egbrink, J. Wagstaff, and A. W. Griffioen Monocyte/macrophage infiltration in tumors: modulators of angiogenesis J. Leukoc. Biol., December 1, 2006; 80(6): 1183 - 1196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Umeda, T. Heike, M. Nakata-Hizume, A. Niwa, M. Arai, G. Shinoda, F. Ma, H. Suemori, H. Y. Luo, D. H. K. Chui, et al. Sequential Analysis of {alpha}- and {beta}-Globin Gene Expression During Erythropoietic Differentiation from Primate Embryonic Stem Cells Stem Cells, December 1, 2006; 24(12): 2627 - 2636. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Mohamedali, A. T. Poblenz, C. R. Sikes, N. M. Navone, P. E. Thorpe, B. G. Darnay, and M. G. Rosenblum Inhibition of Prostate Tumor Growth and Bone Remodeling by the Vascular Targeting Agent VEGF121/rGel. Cancer Res., November 15, 2006; 66(22): 10919 - 10928. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. de Paulis, N. Prevete, I. Fiorentino, F. W. Rossi, S. Staibano, N. Montuori, P. Ragno, A. Longobardi, B. Liccardo, A. Genovese, et al. Expression and Functions of the Vascular Endothelial Growth Factors and Their Receptors in Human Basophils J. Immunol., November 15, 2006; 177(10): 7322 - 7331. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Wu, Z. Zhong, J. Huber, R. Bassi, B. Finnerty, E. Corcoran, H. Li, E. Navarro, P. Balderes, X. Jimenez, et al. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer. Clin. Cancer Res., November 1, 2006; 12(21): 6573 - 6584. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Aplin, M. Gelati, E. Fogel, E. Carnevale, and R. F. Nicosia Angiopoietin-1 and vascular endothelial growth factor induce expression of inflammatory cytokines before angiogenesis Physiol Genomics, October 3, 2006; 27(1): 20 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Lamagna, M. Aurrand-Lions, and B. A. Imhof Dual role of macrophages in tumor growth and angiogenesis J. Leukoc. Biol., October 1, 2006; 80(4): 705 - 713. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Murakami, S. Iwai, S. Hiratsuka, M. Yamauchi, K. Nakamura, Y. Iwakura, and M. Shibuya Signaling of vascular endothelial growth factor receptor-1 tyrosine kinase promotes rheumatoid arthritis through activation of monocytes/macrophages Blood, September 15, 2006; 108(6): 1849 - 1856. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zheng, M. Murakami, H. Takahashi, M. Yamauchi, A. Kiba, S. Yamaguchi, N. Yabana, K. Alitalo, and M. Shibuya Chimeric VEGF-ENZ7/PlGF Promotes Angiogenesis Via VEGFR-2 Without Significant Enhancement of Vascular Permeability and Inflammation Arterioscler. Thromb. Vasc. Biol., September 1, 2006; 26(9): 2019 - 2026. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Li, W. Shen, R. Gill, A. Corbly, B. Jones, R. Belagaje, Y. Zhang, S. Tang, Y. Chen, Y. Zhai, et al. High-Resolution Quantitative Computed Tomography Demonstrating Selective Enhancement of Medium-Size Collaterals by Placental Growth Factor-1 in the Mouse Ischemic Hindlimb Circulation, May 23, 2006; 113(20): 2445 - 2453. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Eisenberg, J. B.E. Burch, and L. M. Eisenberg Bone Marrow Cells Transdifferentiate to Cardiomyocytes When Introduced into the Embryonic Heart Stem Cells, May 1, 2006; 24(5): 1236 - 1245. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Umeda, T. Heike, M. Yoshimoto, G. Shinoda, M. Shiota, H. Suemori, H. Y. Luo, D. H. K. Chui, R. Torii, M. Shibuya, et al. Identification and Characterization of Hemoangiogenic Progenitors During Cynomolgus Monkey Embryonic Stem Cell Differentiation Stem Cells, May 1, 2006; 24(5): 1348 - 1358. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Iwama, S. Uemura, N. Naya, K.-i. Imagawa, Y. Takemoto, O. Asai, K. Onoue, S. Okayama, S. Somekawa, Y. Kida, et al. Cardiac Expression of Placental Growth Factor Predicts the Improvement of Chronic Phase Left Ventricular Function in Patients With Acute Myocardial Infarction J. Am. Coll. Cardiol., April 18, 2006; 47(8): 1559 - 1567. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Fragoso, T. Pereira, Y. Wu, Z. Zhu, J. Cabecadas, and S. Dias VEGFR-1 (FLT-1) activation modulates acute lymphoblastic leukemia localization and survival within the bone marrow, determining the onset of extramedullary disease Blood, February 15, 2006; 107(4): 1608 - 1616. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Campochiaro and the First ARVO/Pfizer Institute Working Group Ocular versus Extraocular Neovascularization: Mirror Images or Vague Resemblances Invest. Ophthalmol. Vis. Sci., February 1, 2006; 47(2): 462 - 474. [Full Text] [PDF]
|
|
|
|
|
|
A. K. Malik, M. E. Baldwin, F. Peale, G. Fuh, W.-C. Liang, H. Lowman, G. Meng, N. Ferrara, and H.-P. Gerber Redundant roles of VEGF-B and PlGF during selective VEGF-A blockade in mice Blood, January 15, 2006; 107(2): 550 - 557. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Vieira, S. C R. Santos, C. Espadinha, I. Correia, T. Vag, C. Casalou, B. M. Cavaco, A. L. Catarino, S. Dias, and V. Leite Expression of vascular endothelial growth factor (VEGF) and its receptors in thyroid carcinomas of follicular origin: a potential autocrine loop Eur. J. Endocrinol., November 1, 2005; 153(5): 701 - 709. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Wilgus, A. M. Matthies, K. A. Radek, J. V. Dovi, A. L. Burns, R. Shankar, and L. A. DiPietro Novel Function for Vascular Endothelial Growth Factor Receptor-1 on Epidermal Keratinocytes Am. J. Pathol., November 1, 2005; 167(5): 1257 - 1266. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Chan, J. Sandhu, A. Guha, D. A. Scollard, J. Wang, P. Chen, K. Bai, L. Lee, and R. M. Reilly A Human Transferrin-Vascular Endothelial Growth Factor (hnTf-VEGF) Fusion Protein Containing an Integrated Binding Site for 111In for Imaging Tumor Angiogenesis J. Nucl. Med., October 1, 2005; 46(10): 1745 - 1752. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Elsheikh, M. Uzunel, Z. He, J. Holgersson, G. Nowak, and S. Sumitran-Holgersson Only a specific subset of human peripheral-blood monocytes has endothelial-like functional capacity Blood, October 1, 2005; 106(7): 2347 - 2355. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Niida, T. Kondo, S. Hiratsuka, S.-I. Hayashi, N. Amizuka, T. Noda, K. Ikeda, and M. Shibuya VEGF receptor 1 signaling is essential for osteoclast development and bone marrow formation in colony-stimulating factor 1-deficient mice PNAS, September 27, 2005; 102(39): 14016 - 14021. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. W. Mould, S. A. Greco, M. M. Cahill, I. D. Tonks, D. Bellomo, C. Patterson, A. Zournazi, A. Nash, P. Scotney, N. K. Hayward, et al. Transgenic Overexpression of Vascular Endothelial Growth Factor-B Isoforms by Endothelial Cells Potentiates Postnatal Vessel Growth In Vivo and In Vitro Circ. Res., September 16, 2005; 97(6): e60 - e70. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Khurana, L. Moons, S. Shafi, A. Luttun, D. Collen, J. F. Martin, P. Carmeliet, and I. C. Zachary Placental Growth Factor Promotes Atherosclerotic Intimal Thickening and Macrophage Accumulation Circulation, May 31, 2005; 111(21): 2828 - 2836. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. A. Mosheimer, N. C. Kaneider, C. Feistritzer, A. M. Djanani, D. H. Sturn, J. R. Patsch, and C. J. Wiedermann Syndecan-1 Is Involved in Osteoprotegerin-Induced Chemotaxis in Human Peripheral Blood Monocytes J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2964 - 2971. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. McGrath-Morrow, C. Cho, C. Cho, L. Zhen, D. J. Hicklin, and R. M. Tuder Vascular Endothelial Growth Factor Receptor 2 Blockade Disrupts Postnatal Lung Development Am. J. Respir. Cell Mol. Biol., May 1, 2005; 32(5): 420 - 427. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Nagai, K. Noda, T. Urano, Y. Kubota, H. Shinoda, T. Koto, K. Shinoda, M. Inoue, T. Shiomi, E. Ikeda, et al. Selective Suppression of Pathologic, but Not Physiologic, Retinal Neovascularization by Blocking the Angiotensin II Type 1 Receptor Invest. Ophthalmol. Vis. Sci., March 1, 2005; 46(3): 1078 - 1084. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Jimenez, D. Lu, L. Brennan, K. Persaud, M. Liu, H. Miao, L. Witte, and Z. Zhu A recombinant, fully human, bispecific antibody neutralizes the biological activities mediated by both vascular endothelial growth factor receptors 2 and 3 Mol. Cancer Ther., March 1, 2005; 4(3): 427 - 434. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Podar and K. C. Anderson The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications Blood, February 15, 2005; 105(4): 1383 - 1395. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. R. Stenmark, N. J. Davie, J. T. Reeves, and M. G. Frid Hypoxia, leukocytes, and the pulmonary circulation J Appl Physiol, February 1, 2005; 98(2): 715 - 721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Dikov, J. E. Ohm, N. Ray, E. E. Tchekneva, J. Burlison, D. Moghanaki, S. Nadaf, and D. P. Carbone Differential Roles of Vascular Endothelial Growth Factor Receptors 1 and 2 in Dendritic Cell Differentiation J. Immunol., January 1, 2005; 174(1): 215 - 222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Nowak, A. Karrar, C. Holmen, S. Nava, M. Uzunel, K. Hultenby, and S. Sumitran-Holgersson Expression of Vascular Endothelial Growth Factor Receptor-2 or Tie-2 on Peripheral Blood Cells Defines Functionally Competent Cell Populations Capable of Reendothelialization Circulation, December 14, 2004; 110(24): 3699 - 3707. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Murdoch, A. Giannoudis, and C. E. Lewis Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues Blood, October 15, 2004; 104(8): 2224 - 2234. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Ostendorf, C. van Roeyen, R. Westenfeld, A. Gawlik, M. Kitahara, E. de Heer, D. Kerjaschki, J. Floege, and M. Ketteler Inducible Nitric Oxide Synthase-Derived Nitric Oxide Promotes Glomerular Angiogenesis via Upregulation of Vascular Endothelial Growth Factor Receptors J. Am. Soc. Nephrol., September 1, 2004; 15(9): 2307 - 2319. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. F. Yang, R. T. Poon, Y. Luo, C. K. Cheung, D. W. Ho, C. M. Lo, and S. T. Fan Up-Regulation of Vascular Endothelial Growth Factor (VEGF) in Small-for-Size Liver Grafts Enhances Macrophage Activities through VEGF Receptor 2-Dependent Pathway J. Immunol., August 15, 2004; 173(4): 2507 - 2515. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M.L. Ebos, G. Bocci, S. Man, P. E. Thorpe, D. J. Hicklin, D. Zhou, X. Jia, and R. S. Kerbel A Naturally Occurring Soluble Form of Vascular Endothelial Growth Factor Receptor 2 Detected in Mouse and Human Plasma Mol. Cancer Res., June 1, 2004; 2(6): 315 - 326. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Umeda, T. Heike, M. Yoshimoto, M. Shiota, H. Suemori, H. Y. Luo, D. H. K. Chui, R. Torii, M. Shibuya, N. Nakatsuji, et al. Development of primitive and definitive hematopoiesis from nonhuman primate embryonic stem cells in vitro Development, April 15, 2004; 131(8): 1869 - 1879. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Walter-Yohrling, S. Morgenbesser, C. Rouleau, R. Bagley, M. Callahan, W. Weber, and B. A. Teicher Murine Endothelial Cell Lines as Models of Tumor Endothelial Cells Clin. Cancer Res., March 15, 2004; 10(6): 2179 - 2189. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Usui, S. Ishida, K. Yamashiro, Y. Kaji, V. Poulaki, J. Moore, T. Moore, S. Amano, Y. Horikawa, D. Dartt, et al. VEGF164(165) as the Pathological Isoform: Differential Leukocyte and Endothelial Responses through VEGFR1 and VEGFR2 Invest. Ophthalmol. Vis. Sci., February 1, 2004; 45(2): 368 - 374. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Chazaud, C. Sonnet, P. Lafuste, G. Bassez, A.-C. Rimaniol, F. Poron, F.-J. Authier, P. A. Dreyfus, and R. K. Gherardi Satellite cells attract monocytes and use macrophages as a support to escape apoptosis and enhance muscle growth J. Cell Biol., December 8, 2003; 163(5): 1133 - 1143. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Okuyama, M. Tsuneto, T. Yamane, H. Yamazaki, and S.-I. Hayashi Discrete Types of Osteoclast Precursors Can Be Generated from Embryonic Stem Cells Stem Cells, November 1, 2003; 21(6): 670 - 680. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-A. Pascaud, F. Griscelli, W. Raoul, E. Marcos, P. Opolon, B. Raffestin, M. Perricaudet, S. Adnot, and S. Eddahibi Lung Overexpression of Angiostatin Aggravates Pulmonary Hypertension in Chronically Hypoxic Mice Am. J. Respir. Cell Mol. Biol., October 1, 2003; 29(4): 449 - 457. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Orecchia, P. M. Lacal, C. Schietroma, V. Morea, G. Zambruno, and C. M. Failla Vascular endothelial growth factor receptor-1 is deposited in the extracellular matrix by endothelial cells and is a ligand for the {alpha}5{beta}1 integrin J. Cell Sci., September 1, 2003; 116(17): 3479 - 3489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Perelman, S. K. Selvaraj, S. Batra, L. R. Luck, A. Erdreich-Epstein, T. D. Coates, V. K. Kalra, and P. Malik Placenta growth factor activates monocytes and correlates with sickle cell disease severity Blood, August 15, 2003; 102(4): 1506 - 1514. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sone, H. Itoh, J. Yamashita, T. Yurugi-Kobayashi, Y. Suzuki, Y. Kondo, A. Nonoguchi, N. Sawada, K. Yamahara, K. Miyashita, et al. Different Differentiation Kinetics of Vascular Progenitor Cells in Primate and Mouse Embryonic Stem Cells Circulation, April 29, 2003; 107(16): 2085 - 2088. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Casella, T. Feccia, C. Chelucci, P. Samoggia, G. Castelli, R. Guerriero, I. Parolini, E. Petrucci, E. Pelosi, O. Morsilli, et al. Autocrine-paracrine VEGF loops potentiate the maturation of megakaryocytic precursors through Flt1 receptor Blood, February 15, 2003; 101(4): 1316 - 1323. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Bachelder, M. A. Wendt, and A. M. Mercurio Vascular Endothelial Growth Factor Promotes Breast Carcinoma Invasion in an Autocrine Manner by Regulating the Chemokine Receptor CXCR4 Cancer Res., December 15, 2002; 62(24): 7203 - 7206. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Hume, I. L. Ross, S. R. Himes, R. T. Sasmono, C. A. Wells, and T. Ravasi The mononuclear phagocyte system revisited J. Leukoc. Biol., October 1, 2002; 72(4): 621 - 627. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Mason, P. Andre, A. Bensussan, C. Buckley, C. Civin, E. Clark, M. de Haas, S. Goyert, M. Hadam, D. Hart, et al. CD antigens 2002 Blood, May 15, 2002; 99(10): 3877 - 3880. [Full Text] [PDF]
|
|
|
|
|
|
A. Adini, T. Kornaga, F. Firoozbakht, and L. E. Benjamin Placental Growth Factor Is a Survival Factor for Tumor Endothelial Cells and Macrophages Cancer Res., May 1, 2002; 62(10): 2749 - 2752. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-i. Minehata, Y.-s. Mukouyama, T. Sekiguchi, T. Hara, and A. Miyajima Macrophage colony stimulating factor modulates the development of hematopoiesis by stimulating the differentiation of endothelial cells in the AGM region Blood, April 1, 2002; 99(7): 2360 - 2368. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Kearney, C. A. Ambler, K.-A. Monaco, N. Johnson, R. G. Rapoport, and V. L. Bautch Vascular endothelial growth factor receptor Flt-1 negatively regulates developmental blood vessel formation by modulating endothelial cell division Blood, April 1, 2002; 99(7): 2397 - 2407. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Mason, P. Andre, A. Bensussan, C. Buckley, C. Civin, E. Clark, M. de Haas, S. Goyert, M. Hadam, D. Hart, et al. CD antigens 2001 J. Leukoc. Biol., November 1, 2001; 70(5): 685 - 690. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Mason, P. Andre, A. Bensussan, C. Buckley, C. Civin, E. Clark, M. de Haas, S. Goyert, M. Hadam, D. Hart, et al. CD Antigens 2001: Aims and Results of HLDA Workshops Stem Cells, November 1, 2001; 19(6): 556 - 562. [Full Text]
|
|
|
|
 |
|
 R. J. Klasa, A. F. List, and B. D. Cheson Rational Approaches to Design of Therapeutics Targeting Molecular Markers Hematology, January 1, 2001; 2001(1): 443 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Papetti and I. M. Herman Mechanisms of normal and tumor-derived angiogenesis Am J Physiol Cell Physiol, May 1, 2002; 282(5): C947 - C970. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2001 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
-protein kinase C-mitogen-activated protein (MAP) kinase
pathway, different from the signal transduction of the representative
receptor tyrosine kinases such as EGF receptor.
) polycarbonate filter, Neuroprobe) was
overlaid; then, in the upper chamber 50 µL of the human monocytes
(1 × 106/mL) was placed and incubated at 37°C for 2 hours in a 5% CO2 incubator. The filter was recovered, and
the cells that migrated from the upper to lower layer were stained with
Diff-Quik (Kokusai-Shiyaku, Kobe, Japan). The migrated
monocytes were counted in 10 areas under a microscope to obtain an
average value of cell migration.
-MEM supplemented with a cytokine mixture of interleukin (IL)-3
(200 U/mL, Kirin, Tokyo, Japan), IL-6 (200 U/mL, Ajinomoto, Tokyo,
Japan), macrophage colony-stimulating factor (M-CSF; 100 ng/mL,
Morinaga Milk Industry, Tokyo, Japan), granulocyte-macrophage
colony-stimulating factor (GM-CSF; 20 ng/mL, Kirin), and Flt-3
ligand (100 ng/mL, R&D Systems, Minneapolis, MN).
) and control
KM231 (
) are shown. Arrowhead (dashed line), inhibitor 0 µg/mL.
(B) Flow cytometric analysis of HUVEC, binding with antihuman Flt-1
mAbs, KM1730 and KM1732, or antihuman KDR mAb, KM1992. HUVECs were
stained with KM1730, KM1732, KM1992, or control mouse IgG1 mAb and
analyzed by flow cytometry.
) and
mononuclear (
) osteoclasts started from 3 × 104
Flt-1+CD11b+ or
Flt-1++CD11b++ cells are indicated in
panel C.